Home > Product Portfolio > Late Stage
Products in Late Stage Development
Spectrum has two late-stage drug candidates including SPI-2012, a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that is being investigated for the treatment of chemotherapy-induced neutropenia in patients with breast cancer, and Apaziquone, a synthetic bio-reductive agent being investigated in the treatment of non-muscle invasive bladder cancer.
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law.
|All contents copyright Spectrum Pharmaceuticals, Inc. © 2016.
All Rights Reserved. PP-ALL-00-0012
Contact Us | Webmail